Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease

作者: Christiane Auray-Blais , Denis Cyr , Aimé Ntwari , Michael L. West , Josanne Cox-Brinkman

DOI: 10.1016/J.YMGME.2007.10.001

关键词:

摘要: Fabry disease is a complex, multisystemic and clinically heterogeneous disease, in which the urinary excretion of globotriaosylceramide (Gb3), principal substrate deficient enzyme, alpha-galactosidase A, more prominent than increased concentrations lipid plasma affected hemizygotes heterozygotes. We have developed validated simultaneous analysis Gb3 creatinine 2.6-min run using filter paper discs saturated with urine analyzed by LC-MS/MS. Using this method, we studied relationship between levels total Gb3/creatinine four types mutations GLA gene (missense, nonsense, frameshift, splice-site defects) 32 children 78 adult patients disease. Forty-one were treated enzyme replacement therapy 69 untreated. Our results show that mean recoveries from standards 91% 97%, respectively, precision, reproducibility, linearity within acceptable ranges. Statistical independent variables sex, age, treatment showed mutation factor has statistically significant impact on (p = 0.0007). This means adults are directly related to mutations. The same correlation was found for sex < 0.0001) 0.0011). In conclusion, 35 110 patients.

参考文章(45)
GM Altarescu, LG Goldfarb, K-Y Park, C Kaneski, N Jeffries, S Litvak, JW Nagle, R Schiffmann, Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clinical Genetics. ,vol. 60, pp. 46- 51 ,(2001) , 10.1034/J.1399-0004.2001.600107.X
R J Desnick, K H Astrin, C M Eng, L A Resnick-Silverman, D J Niehaus, Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. American Journal of Human Genetics. ,vol. 53, pp. 1186- 1197 ,(1993)
Christiane Auray-Blais, Johane Patenaude, A biobank management model applicable to biomedical research BMC Medical Ethics. ,vol. 7, pp. 4- ,(2006) , 10.1186/1472-6939-7-4
Atul Mehta, Gere Sunder-Plassmann, Michael Beck, Fabry Disease: Perspectives from 5 Years of FOS Oxford Pharmagenesis (2006). ,(2006)
Dominique P. Germain, Junaid Shabbeer, Sylvie Cotigny, Robert J. Desnick, Fabry disease: twenty novel alpha-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes. Molecular Medicine. ,vol. 8, pp. 306- 312 ,(2002) , 10.1007/BF03402156
AC Vedder, GE Linthorst, MJ Van Breemen, JEM Groener, FJ Bemelman, A Strijland, MMAM Mannens, JMFG Aerts, CEM Hollak, None, The Dutch Fabry cohort: Diversity of clinical manifestations and Gb3 levels Journal of Inherited Metabolic Disease. ,vol. 30, pp. 68- 78 ,(2007) , 10.1007/S10545-006-0484-8
Toshika Okumiya, Satoshi Ishii, Ryoichi Kase, Sachiko Kamei, Hitoshi Sakuraba, Yoshiyuki Suzuki, α-Galactosidase gene mutations in Fabry disease : heterogeneous expressions of mutant enzyme proteins Human Genetics. ,vol. 95, pp. 557- 561 ,(1995) , 10.1007/BF00223869
C. Auray-Blais, D. Cyr, K. Mills, R. Giguère, R. Drouin, Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease Journal of Inherited Metabolic Disease. ,vol. 30, pp. 106- 106 ,(2007) , 10.1007/S10545-006-0444-3
Joe T.R. Clarke, Narrative review: Fabry disease. Annals of Internal Medicine. ,vol. 146, pp. 425- 433 ,(2007) , 10.7326/0003-4819-146-6-200703200-00007
Raphael Schiffmann, Enzyme replacement in Fabry disease: the essence is in the kidney. Annals of Internal Medicine. ,vol. 146, pp. 142- 144 ,(2007) , 10.7326/0003-4819-146-2-200701160-00147